Drug recall · January 29, 2020
Nizatidine Capsules recall
Why: CGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the API Nizatidine.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Nizatidine Capsules, USP 300 mg, Rx Only, Mylan Pharmaceuticals Inc., NDC 0378-5300-93.
- Lots / codes
Lot # 3082876, exp. date January 2020 Lot # 3082877, exp. date January 2020
- Quantity
- 16,944 bottles of 30 capsules
- Company
- Mylan Pharmaceuticals Inc., Morgantown, WV
- Distribution
- Product was distributed to wholesalers, distributors , retail pharmacies, charitable organizations and mail order pharmacies throughout the United States and the product may have been further distributed.
- Initiated
- January 7, 2020 · Voluntary: Firm initiated
- Classified
- January 20, 2020
- Reported
- January 29, 2020
- Ended
- May 19, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Nizatidine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.